Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lalikinogene sifuplasmid-gxfd
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Lalikinogene sifuplasmid-gxfd (pGX6010) is a recombinant DNA plasmid encoding human interleukin-12 (IL-12) subunits alpha (p35) and beta (p40). Developed by Inovio, it is designed to act as an immune-enhancing adjuvant. It is co-formulated with doruxapapogene ralaplasmid (pGX3024), which encodes HPV-6 and HPV-11 E6/E7 antigens, to form the combination immunotherapy Voceryq (previously INO-3107). Voceryq was granted accelerated approval by the FDA in October 2026 for the treatment of recurrent respiratory papillomatosis (RRP) in adults to reduce the frequency of surgical papilloma excisions. Lalikinogene sifuplasmid-gxfd is administered intramuscularly followed by electroporation using the CELLECTRA 5PSP device, which facilitates cellular uptake of the plasmid, leading to local expression of IL-12 and the promotion of a robust, antigen-specific T-cell response against HPV-infected cells.
- Other names
- lalikogene sifuplasmid-gxfdlalikinogene sifuplasmidpGX6010 plasmidpGX-6010 plasmidpGX 6010 plasmidrecombinant plasmid vector pGX6010
02
Targets
IL12 (Interleukin-12)
Beyond the preview
Go deeper on lalikinogene sifuplasmid-gxfd.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lalikinogene sifuplasmid-gxfd.